



Glutamate Receptor in Health and Development

Guest Editor:

Dr. Chin-Wei Huang

Department of Neurology,
National Cheng Kung University
Hospital, College of Medicine,
National Cheng Kung University,
Tainan 70101, Taiwan

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editor

Glutamate is an essential excitatory neurotransmitter in the central nervous system that is involved indispensably in neuronal development and memory formation. Glutamate receptors, which mediate major excitatory synaptic transmission, regulate a wide spectrum of biological processes in normal development and health. The dysregulation of glutamate receptors and the glutamatergic system is involved in numerous neurological and psychiatric disorders. There are two main classes of glutamate receptors, ionotropic and metabotropic (mGluRs) receptors. The former stimulate fast excitatory neurotransmission and include N-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainite; while the latter are G protein-coupled receptors mediating glutamatergic activity via intracellular messenger systems. In this Special Issue, we wish to focus on a broad spectrum of basic and clinical studies on glutamate receptors in human development, health and disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)